

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VENTUREPHARM LABORATORIES LIMITED**

**萬全科技藥業有限公司\***

*( incorporated in the Cayman Islands with limited liability )*

**(Stock Code:8225)**

### **CLARIFICATION ANNOUNCEMENT**

Reference is made to the announcement of Venturepharm Laboratories Limited (the Company”) dated 31 March 2011 (the “Announcement”) in relation to further postponement of board meeting.

The Board wishes to clarify that there was an incorrect reference to the time of suspending Trading. And paragraph 2 of page 1 should be replaced by the following:

At the request of the Company, trading in the securities of the Company on the Stock Exchange will be suspended from 9:00 a.m. on April 1, 2011 and will remain suspended until the release of an announcement relating to the publication of its annual results and despatch of its annual report for the Year ended December 31, 2010.

By order of the Board  
Venturepharm Laboratories Limited  
William Xia Guo  
Chairman

Beijing, the PRC, 31 March 2011

*\* For identification purpose only*

*As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Wu Xin and Dr. Nathan Xin*

Zhang; and three independent non-executive directors, being Mr. Wang Hong Bo, Mr. Paul Contomichalos and Mr. Wu Ming Yu.

*This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the GEM website with the domain name of [www.hkgem.com](http://www.hkgem.com) on the “Latest Company Announcements” page for at least 7days from the date of its posting and on the Company’s website at [www.venturepharm.com](http://www.venturepharm.com)*